Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

303.74 +2.94 (+0.98%)

Streaming Delayed Price Updated: 2:50 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications

December 01, 2023

From Palvella Therapeutics

Via GlobeNewswire

Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's ↗

November 28, 2023

Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent

Via Benzinga

Ligand Reports Third Quarter 2023 Financial Results

November 08, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million

November 01, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Where Ligand Pharmaceuticals Stands With Analysts ↗

September 19, 2023

Via Benzinga

Analyst Expectations for Ligand Pharmaceuticals's Future ↗

August 23, 2023

Via Benzinga

Ligand To Report Third Quarter 2023 Financial Results On November 8

October 25, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

October 18, 2023

From Ovid Therapeutics Inc.

Via GlobeNewswire

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

September 27, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Recap: Ligand Pharmaceuticals Q1 Earnings ↗

May 04, 2023

Via Benzinga

Ligand Pharmaceuticals Earnings Preview ↗

February 21, 2023

Via Benzinga

Ligand Appoints Martine Zimmermann to its Board of Directors

September 26, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

September 22, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

September 21, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary ↗

September 19, 2023

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) entered into a merger agreement under which its subsidiary, Pelican Technology Holdings Inc, has become a wholly owned subsidiary of Primrose Bio...

Via Benzinga

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

September 18, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

September 01, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Second Quarter 2023 Financial Results

August 08, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 27, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand To Report Second Quarter 2023 Financial Results On August 8

July 25, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Why Are Novan Shares Nosediving Today? ↗

July 17, 2023

Novan Inc (NASDAQ: NOVN) shares are trading lower after Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has offered to

Via Benzinga

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

July 17, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection

July 17, 2023

From Novan, Inc.

Via GlobeNewswire

3 Stocks That Smart Investors Should Be Flocking to Now ↗

May 30, 2023

Investors may want to detour away from the obvious trades and consider compelling top stocks for smart investors.

Via InvestorPlace

Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial ↗

May 16, 2023

Ligand Pharmaceuticals Incorporated's (NASDAQ: LGND) partner Viking Therapeutics Inc (NASDAQ: VKTX) announced positive topline results from its Phase 2b trial of VK2809 in

Via Benzinga

Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

May 16, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports First Quarter 2023 Financial Results

May 04, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

April 24, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Earnings Scheduled For February 22, 2023 ↗

February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.